| Literature DB >> 33397903 |
Rafael R de Assis1, Aarti Jain1, Rie Nakajima1, Algis Jasinskas1, Jiin Felgner1, Joshua M Obiero1, Philip J Norris2,3, Mars Stone2,3, Graham Simmons2,3, Anil Bagri4, Johannes Irsch4, Martin Schreiber5, Andreas Buser6, Andreas Holbro5, Manuel Battegay6, Philip Hosimer7, Charles Noesen7, Oluwasanmi Adenaiye8, Sheldon Tai8, Filbert Hong8, Donald K Milton8, D Huw Davies1, Paul Contestable7, Laurence M Corash4, Michael P Busch2,3, Philip L Felgner1, Saahir Khan9.
Abstract
The current practice for diagnosis of COVID-19, based on SARS-CoV-2 PCR testing of pharyngeal or respiratory specimens in a symptomatic patient at high epidemiologic risk, likely underestimates the true prevalence of infection. Serologic methods can more accurately estimate the disease burden by detecting infections missed by the limited testing performed to date. Here, we describe the validation of a coronavirus antigen microarray containing immunologically significant antigens from SARS-CoV-2, in addition to SARS-CoV, MERS-CoV, common human coronavirus strains, and other common respiratory viruses. A comparison of antibody profiles detected on the array from control sera collected prior to the SARS-CoV-2 pandemic versus convalescent blood specimens from virologically confirmed COVID-19 cases demonstrates near complete discrimination of these two groups, with improved performance from use of antigen combinations that include both spike protein and nucleoprotein. This array can be used as a diagnostic tool, as an epidemiologic tool to more accurately estimate the disease burden of COVID-19, and as a research tool to correlate antibody responses with clinical outcomes.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33397903 PMCID： PMC7782488 DOI： 10.1038/s41467-020-20095-2
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919